NEW YORK, October 27, 2017 /PRNewswire/ --
If you want a Stock Review on IMNP, ZGNX, SHPG, or ABBV then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com has lined up four major players in the Drug Manufacturers space for assessment this morning: Immune Pharmaceuticals Inc. (NASDAQ: IMNP),
Shares in Englewood Cliffs, New Jersey headquartered Immune Pharmaceuticals Inc. saw a correction of 7.50%, ending Thursday's trading session at $0.85. The stock recorded a trading volume of 695,440 shares. The Company's shares are trading 33.34% below their 50-day moving average. Moreover, shares of Immune Pharma, which develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology, have a Relative Strength Index (RSI) of 28.92. Visit us today and access your complete report on IMNP for free at:
Emeryville, California headquartered Zogenix Inc.'s stock climbed 1.58%, closing the day at $38.65 with a total trading volume of 635,703 shares. The Company's shares have skyrocketed 175.09% in the past month, 210.44% in the previous three months, and 218.11% since the start of this year. The stock is trading 67.78% and 166.58% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Zogenix, which develops and commercializes therapies for the treatment of central nervous system disorders in the US, have an RSI of 70.02.
On October 03rd, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $28 a share to $51 a share.
On October 05th, 2017, Zogenix announced the closing of its previously announced underwritten public offering of 7,705,000 shares of its common stock, including 1,005,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $37.50 per share. The gross proceeds from the offering, before underwriting discounts and commissions and offering costs, are $288,937,500. The complimentary research report on ZGNX can be accessed at:
On Thursday, shares in Dublin, Ireland headquartered Shire PLC recorded a trading volume of 1.74 million shares, which was higher than their three months average volume of 1.16 million shares. The stock ended the day 3.79% lower at $138.24. The Company's shares are trading below their 50-day moving average by 8.63%. Furthermore, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have an RSI of 29.40.
On October 19th, 2017, research firm FBR & Co. initiated a 'Buy' rating on the Company's stock, with a target price of $201 per share.
On October 26th, 2017, Shire announced that the European Commission has approved a label extension granting a new indication for FIRAZYR® (icatibant injection), broadening its use to adolescents and children aged two years and older with hereditary angioedema (HAE) caused by C1-esterase-inhibitor (C1-INH) deficiency. FIRAZYR has been approved in the European Union since 2008 for symptomatic treatment of acute attacks of HAE in adults with C1-INH deficiency. Register for free on DailyStockTracker.com and download the research report on SHPG at:
North Chicago, Illinois-based AbbVie Inc.'s stock dropped 2.41%, finishing yesterday's session at $89.56. A total volume of 10.27 million shares was traded, which was above their three months average volume of 6.56 million shares. The Company's shares have advanced 5.68% in the last one month, 27.14% in the previous three months, and 43.02% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.98% and 26.10%, respectively. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 50.66.
On October 02nd, 2017, research firm Leerink Partners upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On October 25th, 2017, AbbVie announced that Health Canada has approved the inclusion of nail psoriasis data in the HUMIRA Product Monograph. HUMIRA is approved for use in adult patients with chronic moderate to severe plaque psoriasis. This label update for HUMIRA stemmed from the results of the Nail Psoriasis Pivotal Trial M13-674, a trial specifically evaluating two primary endpoints of nail psoriasis. Get free access to your research report on ABBV at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All